Photo of Rebecca A. Miksad,  MD, MPH

Rebecca A. Miksad, MD, MPH

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2100
Fax: (617) 975-5665

Rebecca A. Miksad, MD, MPH

Beth Israel Deaconess Medical Center


  • Assistant Professor, Medicine, Harvard Medical School
  • Physician-Investigator, Hematology/Oncology, Beth Israel Deaconess Medical Center
  • Director, Gastrointestinal Oncology, Oncology, Beth Israel Deaconess Medical Center


Research Abstract

Dr. Miksad's research goal is to improve treatments and outcomes for patients with Hepatobiliary and Pancreatic Cancer. She is engaged in translational clinical trial and health services/outcomes research as an Attending Physician in medical oncology at Beth Israel Deaconess Medical Center and as Senior Scientist at the Institute for Technology Assessment at Massachusetts General Hospital. Dr. Miksad's research is currently supported by a K23 from the National Cancer Institute.

Dr. Miksad's past research support includes the Young InvestigatorAward from the American Society of Clinical Oncology, the DF/HCC Program in Cancer Outcomes Research (PCORT) fellowship, the Young Investigator’s Award from the American Society of Clinical Oncology, the Timely Special Opportunity Award from the Dana-Farber Cancer Institute, the NIH Loan Repayment Program and the Clinical Research Feasibility Fund Award from BIDMC. Recent awards include the Lee Lusted Prize for outstanding research from the Society for Medical Decision Making and the Clinical Research Award from the Eastern Cooperative Oncology Group.

Dr. Miksad received a B.A in economics from Harvard, an MD with honors in research from Cornell University, and an MPH from Harvard. She completed her internal medicine residency at New York-Presbyterian Hospital and her Hematology/Oncology fellowship at BIDMC. She completed the NCI-funded post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT). Rebecca’s research goals are to improve oncology treatment decision making through better characterization of cancer patient outcomes, improved accuracy of clinical endpoints, assessment of the economic implications of cancer therapy and application of decision analysis tools. Dr. Miksad current and recent research projects include:

1) Efficacy neoadjuvant sorafenib for radiofrequency ablation of localized hepatocellular carcinoma (HCC)

2) Hepatobiliary cancer clinical trials and liver cancer outcomes

3) Surrogate endpoint evaluation and validation in cancer trials

4) Bayesian analysis / novel oncology clinical trial evaluation

5) Decision analysis and cancer modeling

6) Quality of life of cancer patients


Powered by Harvard Catalyst
  • Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Bui JL, Yuan C, Qian ZR, Babic A, Da Silva A, Nowak JA, Khalaf N, Brais LK, Welch MW, Zellers CL, Ng K, Chang DT, Miksad RA, Bullock AJ, Tseng JF, Swanson RS, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Hornick JL, Ogino S, Fuchs CS, Hezel AF, Koong AC, Wolpin BM. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival. Br J Cancer 2017. PubMed
  • Kasumova GG, Eskander MF, de Geus SWL, Neto MM, Tabatabaie O, Ng SC, Miksad RA, Mahadevan A, Rodrigue JR, Tseng JF. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy. Surgery 2017. PubMed
  • Burstein HJ, Krilov L, Aragon-Ching JB, Baxter NN, Chiorean EG, Chow WA, De Groot JF, Devine SM, DuBois SG, El-Deiry WS, Epstein AS, Heymach J, Jones JA, Mayer DK, Miksad RA, Pennell NA, Sabel MS, Schilsky RL, Schuchter LM, Tung N, Winkfield KM, Wirth LJ, Dizon DS. Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol 2017. PubMed
  • Kasumova GG, Miksad RA, Tseng JF. Cutting Through Confusion: Multimodality Therapy in Borderline Resectable and Locally Advanced Pancreatic Cancer. J Oncol Pract 2016; 12:924-925. PubMed
  • Peters ML, Tseng JF, Miksad RA. Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment. Clin Ther 2016. PubMed
  • Griffith OL, Griffith M, Krysiak K, Magrini V, Ramu A, Skidmore ZL, Kunisaki J, Austin R, McGrath S, Zhang J, Demeter R, Graves T, Eldred JM, Walker J, Larson DE, Maher CA, Lin Y, Chapman W, Mahadevan A, Miksad R, Nasser I, Hanto DW, Mardis ER. A genomic case study of mixed fibrolamellar hepatocellular carcinoma. Ann Oncol 2016. PubMed
  • Bhasin MK, Ndebele K, Bucur O, Yee EU, Otu HH, Plati J, Bullock A, Gu X, Castan E, Zhang P, Najarian R, Muraru MS, Miksad R, Khosravi-Far R, Libermann TA. Meta-analysis of transcriptome data identifies a novel 5-gene pancreatic adenocarcinoma classifier. 2016. PubMed
  • Miao R, Wu Y, Zhang H, Zhou H, Sun X, Csizmadia E, He L, Zhao Y, Jiang C, Miksad RA, Ghaziani T, Robson SC, Zhao H. Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer. Sci Rep 2016; 6:33121. PubMed
  • Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, O'Beirne J, Fox R, Skowronska A, Palmer D, Yeo W, Mo F, Lai P, Iñarrairaegui M, Chan SL, Sangro B, Miksad R, Tada T, Kumada T, Toyoda H. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol 2015; 33:550-8. PubMed
  • Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer 2015; 6:1099-104. PubMed
  • Miao R, Luo H, Zhou H, Li G, Bu D, Yang X, Zhao X, Zhang H, Liu S, Zhong Y, Zou Z, Zhao Y, Yu K, He L, Sang X, Zhong S, Huang J, Wu Y, Miksad RA, Robson SC, Jiang C, Zhao Y, Zhao H. Identification of prognostic biomarkers in hepatitis B virus-related hepatocellular carcinoma and stratification by integrative multi-omics analysis. J Hepatol 2014. PubMed
  • Beard RE, Hanto DW, Gautam S, Miksad RA. A comparison of surgical outcomes for noncirrhotic and cirrhotic hepatocellular carcinoma patients in a Western institution. Surgery 2013; 154:545-55. PubMed
  • Doherty GA, Miksad RA, Cheifetz AS, Moss AC. Comparative cost-effectiveness of strategies to prevent postoperative clinical recurrence of Crohn's disease. Inflamm Bowel Dis 2012. PubMed
  • Chan JA, Stuart K, Earle CC, Clark JW, Bhargava P, Miksad R, Blaszkowsky L, Enzinger PC, Meyerhardt JA, Zheng H, Fuchs CS, Kulke MH. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30:2963-8. PubMed
  • Miksad RA. When a decision must be made: role of computer modeling in clinical cancer research. J Clin Oncol 2011; 29:4602-4. PubMed
  • Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M. Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Int J Radiat Oncol Biol Phys 2011. PubMed
  • Zhu AX, Abrams TA, Miksad R, Blaszkowsky LS, Meyerhardt JA, Zheng H, Muzikansky A, Clark JW, Kwak EL, Schrag D, Jors KR, Fuchs CS, Iafrate AJ, Borger DR, Ryan DP. Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer 2011. PubMed
  • Duvoux C, Kiuchi T, Pestalozzi B, Busuttil R, Miksad R. What is the role of adjuvant therapy after liver transplantation for hepatocellular carcinoma? Liver Transpl 2011; 17 Suppl 2:S147-58. PubMed
  • Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, Bihrle M, Maytal G, August M, Gazelle GS, Swan JS. Quality of life implications of bisphosphonate-associated osteonecrosis of the jaw. Oncologist 2011; 16:121-32. PubMed
  • Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C. Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys 2010; 78:735-42. PubMed
  • Zhu AX, Duda DG, Ancukiewicz M, di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP, Jain RK. Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin Cancer Res 2010. PubMed
  • Kamo N, Dandapani SV, Miksad RA, Houlihan MJ, Kaplan I, Regan M, Greenfield TK, Sanda MG. Evaluation of the SCA instrument for measuring patient satisfaction with cancer care administered via paper or via the Internet. Ann Oncol 2010. PubMed
  • Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010; 15:1179-91. PubMed
  • Swan JS, Miksad RA. Measuring the quality-of-life effects of diagnostic and screening tests. J Am Coll Radiol 2009; 6:567-75. PubMed
  • Zhu AX,Sahani DV,Duda DG,di Tomaso E,Ancukiewicz M,Catalano OA,Sindhwani V,Blaszkowsky LS,Yoon SS,Lahdenranta J,Bhargava P,Meyerhardt J,Clark JW,Kwak EL,Hezel AF,Miksad R,Abrams TA,Enzinger PC,Fuchs CS,Ryan DP,Jain RK. Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study. J Clin Oncol 2009; 27:3027-35. PubMed
  • Miksad RA,Gonen M,Lynch TJ,Roberts TG Jr. Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer. J Clin Oncol 2009; 27:2245-52. PubMed
  • Wright DR, Wittenberg E, Swan JS, Miksad RA, Prosser LA. Methods for measuring temporary health States for cost-utility analyses. 2009; 27:713-23. PubMed
  • Miksad RA, Lai KC, Stein MC, Healy ME, Rojas R, Krajewski KM, Zhu AX. Imbalance and gait disturbance from tyrosine kinase inhibition in hepatocellular cancer. J Gastrointest Cancer 2010; 40:119-22. PubMed
  • Miksad RA,Zietemann V,Gothe R,Schwarzer R,Conrads-Frank A,Schnell-Inderst P,Stollenwerk B,Siebert U. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care 2008; 24:371-83. PubMed
  • Muhlberger N, Sroczynski G, Esteban E, Mittendorf T, Miksad RA, Siebert U. Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. Int J Technol Assess Health Care 2008; 24:184-92. PubMed
  • Molokwu CN, Appelbaum JS, Miksad RA. Detection of prostate cancer following gender reassignment. BJU Int 2008; 101:259; author reply 259-60. PubMed
  • Miksad RA, Schnipper L, Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value? J Clin Oncol 2007; 25:4506-7; author reply 4508. PubMed
  • Silva G, Miksad R, Freedman SD, Pascual-Leone A, Jain S, Gomes DL, Amancio EJ, Boggio PS, Correa CF, Fregni F. Treatment of cancer pain with noninvasive brain stimulation. J Pain Symptom Manage 2007; 34:342-5. PubMed
  • Miksad RA, Bubley G, Church P, Sanda M, Rofsky N, Kaplan I, Cooper A. Prostate cancer in a transgender woman 41 years after initiation of feminization. JAMA 2006; 296:2316-7. PubMed
  • Costa DB, Miksad RA, Buff MS, Wang Y, Dezube BJ. Case of fatal sickle cell intrahepatic cholestasis despite use of exchange transfusion in an African-American patient. J Natl Med Assoc 2006; 98:1183-7. PubMed
  • Levy NC, Miksad RA, Fein OT. From treatment to prevention: the interplay between HIV/AIDS treatment availability and HIV/AIDS prevention programming in Khayelitsha, South Africa. J Urban Health 2005; 82:498-509. PubMed
  • Miksad R, de L. Hepatic hydrothorax associated with vitamin a toxicity. J Clin Gastroenterol 2002; 34:275-9. PubMed